Literature DB >> 12933462

Adverse events during radiofrequency treatment of 582 hepatic tumors.

Thierry de Baère1, Olivier Risse, Viseth Kuoch, Clarisse Dromain, Christophe Sengel, Tarek Smayra, Mostafa Gamal El Din, Christian Letoublon, Dominique Elias.   

Abstract

OBJECTIVE: We describe the rates and potential risk factors of complications of radiofrequency ablation of hepatic tumors. SUBJECTS AND METHODS. Over a 5-year period, 312 patients underwent 350 sessions of radiofrequency ablation (124 intraoperative and 226 percutaneous) for treatment of 582 liver tumors including 115 hepatocellular carcinomas and 467 metastatic tumors. The chi-square test was used for a group-to-group comparison of the occurrence of adverse events.
RESULTS: Thirty-seven (10.6%) adverse events and five (1.4%) deaths were related to radiofrequency treatment. The deaths were caused by liver insufficiency (n = 1), colon perforation (n = 1), and portal vein thrombosis (n = 3). Portal vein thrombosis was significantly (p < 0.00001) more frequent in cirrhotic livers (2/5) than in noncirrhotic livers (0/54) after intraoperative radiofrequency ablation performed during a Pringle maneuver. Liver abscess (n = 7) was the most common complication. Abscess occurred significantly (p < 0.00001) more frequently in patients bearing a bilioenteric anastomosis (3/3) than in other patients (4/223). We encountered five pleural effusions, five skin burns, four hypoxemias, three pneumothoraces, two small subcapsular hematomas, one acute renal insufficiency, one hemoperitoneum, and one needle-tract seeding. The 6.3% of minor complications did not require specific treatment or a prolonged hospital stay. Among the 5.7% major complications, 3.7% required less than 5 days of hospitalization for treatment or surveillance and 2% required more than 5 days for treatment.
CONCLUSION: Radiofrequency ablation of liver tumors is a well-tolerated technique, but caution should be exercised when treating patients with a bilioenteric anastomosis, and radiofrequency ablation during vascular occlusion in cirrhotic livers should be avoided.

Entities:  

Mesh:

Year:  2003        PMID: 12933462     DOI: 10.2214/ajr.181.3.1810695

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  84 in total

Review 1.  Complications after percutaneous ablation of liver tumors: a systematic review.

Authors:  Eylon Lahat; Rony Eshkenazy; Alex Zendel; Barak Bar Zakai; Mayan Maor; Yael Dreznik; Arie Ariche
Journal:  Hepatobiliary Surg Nutr       Date:  2014-10       Impact factor: 7.293

2.  Thermal protection during percutaneous thermal ablation of renal cell carcinoma.

Authors:  Anthony W Kam; Peter J Littrup; McClellan M Walther; Julia Hvizda; Bradford J Wood
Journal:  J Vasc Interv Radiol       Date:  2004-07       Impact factor: 3.464

Review 3.  Treatment of hepatocarcinoma.

Authors:  Beatrice Gerard; Harry Bleiberg
Journal:  Curr Oncol Rep       Date:  2004-05       Impact factor: 5.075

4.  [Laser ablation. Do we still need it?].

Authors:  C Rosenberg; C O M Hoffmann; B Mensel; R Puls; N Hosten
Journal:  Radiologe       Date:  2012-01       Impact factor: 0.635

Review 5.  Complications of intraoperative radiofrequency ablation of liver metastases.

Authors:  Tsiriniaina Razafindratsira; Milène Isambert; Serge Evrard
Journal:  HPB (Oxford)       Date:  2010-12-07       Impact factor: 3.647

6.  Thermo-sensitive hydrogel for preventing bowel injury in percutaneous renal radiofrequency ablation.

Authors:  Xin Wang; Xiaozhi Zhao; Tingsheng Lin; Hongqian Guo
Journal:  Int Urol Nephrol       Date:  2016-07-09       Impact factor: 2.370

7.  Radiofrequency ablation for hepatocellular carcinoma: use of low vs maximal radiofrequency power.

Authors:  T C Macatula; C-C Lin; C-J Lin; W-T Chen; S-M Lin
Journal:  Br J Radiol       Date:  2011-03-22       Impact factor: 3.039

Review 8.  Radiofrequency thermal ablation of liver tumors.

Authors:  Elisabetta Buscarini; Agostino Savoia; Gianfranco Brambilla; Fernanda Menozzi; Luigi Reduzzi; Deike Strobel; Johannes Hänsler; Luigi Buscarini; Luigi Gaiti; Alessandro Zambelli
Journal:  Eur Radiol       Date:  2005-03-08       Impact factor: 5.315

9.  2014 KLCSG-NCC Korea Practice Guideline for the Management of Hepatocellular Carcinoma.

Authors: 
Journal:  Gut Liver       Date:  2015-05-23       Impact factor: 4.519

10.  Percutaneous radiofrequency ablation versus surgical radiofrequency ablation for malignant liver tumours: the long-term results.

Authors:  John Wong; Kit-Fai Lee; Simon Chun-Ho Yu; Paul Sing-Fun Lee; Yue-Sun Cheung; Ching-Ning Chong; Philip Ching-Tak Ip; Paul Bo-San Lai
Journal:  HPB (Oxford)       Date:  2012-11-28       Impact factor: 3.647

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.